Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, Devriese LA, Opdam FL, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. van Geel RMJM, et al. Among authors: lolkema mpjk. Br J Cancer. 2020 Apr;122(8):1166-1174. doi: 10.1038/s41416-020-0776-z. Epub 2020 Mar 9. Br J Cancer. 2020. PMID: 32147669 Free PMC article. Clinical Trial.
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N. Lankheet NA, et al. Br J Cancer. 2014 May 13;110(10):2441-9. doi: 10.1038/bjc.2014.194. Epub 2014 Apr 15. Br J Cancer. 2014. PMID: 24736581 Free PMC article. Clinical Trial.
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HMW, Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE. Langenberg MHG, et al. Ann Oncol. 2011 Nov;22(11):2508-2515. doi: 10.1093/annonc/mdq767. Epub 2011 Mar 4. Ann Oncol. 2011. PMID: 21378200 Free article. Clinical Trial.
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE. Cirkel GA, et al. Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234642 Free article. Clinical Trial.
40 results